In this episode of Huberman Lab Essentials, my guest is Dr. Karl Deisseroth, M.D., Ph.D., a clinical psychiatrist and professor of bioengineering and of psychiatry and behavioral sciences at Stanford University.

We discuss his experiences as a clinician treating complex psychiatric conditions and his lab’s pioneering work in developing transformative therapies for mental illness. He explains the complexities of mental illness and how emerging technologies—such as optogenetics and brain-machine interfaces—could revolutionize care. We also explore promising new therapies, including psychedelics and MDMA, for conditions like depression and PTSD.

Read the episode show notes at hubermanlab.com.

Huberman Lab Essentials are short episodes focused on essential science and protocol takeaways from past full-length Huberman Lab episodes. Watch or listen to the full-length episode at ⁠hubermanlab.com⁠.

Thank you to our sponsors

AG1: https://drinkag1.com/huberman

David: https://davidprotein.com/huberman

Eight Sleep: https://eightsleep.com/huberman

Timestamps

00:00:00 Karl Deisseroth; Neurology vs Psychiatry

00:01:36 Speech; Blood Test?; Seeking Help

00:04:20 Feelings, Jargon; Psychiatric Treatment

00:09:40 Sponsor: David

00:10:55 Future Treatment; Vagus Nerve Stimulation, Depression, Optogenetics

00:19:40 Brain-Machine Interfaces

00:20:53 Sponsor: Eight Sleep

00:23:00 ADHD Symptoms, Lifestyle, Technology

00:29:34 Psychedelics, Depression Treatment, Risks

00:35:43 Sponsor: AG1

00:37:30 MDMA (Ecstasy), Trauma & Post-Traumatic Stress Disorder (PTSD) Treatment

00:40:33 Projections: A Story of Human Emotions Book, Optimism

Disclaimer & Disclosures

Learn more about your ad choices. Visit megaphone.fm/adchoices